
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's updated earnings per share (EPS) estimate for 2025 has been increased to $17.06, reflecting positive second-quarter results and revised guidance, indicating a strong financial performance outlook. Furthermore, the company's anticipated year-over-year earnings growth for 2027, alongside its initiatives for margin improvement, suggests effective operational management in the face of potential reimbursement challenges. Additionally, Humana's superior Medicare Advantage star rating profile enhances its competitive position, providing an advantage amid evolving regulatory landscapes.
Bears say
Humana's future earnings per share (EPS) are projected to decline slightly in 2026 due to headwinds from the Stars program, even though margins are expected to improve as part of management's initiatives. Significant risks impacting the company's performance include increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining membership in the Prescription Drug Plan (PDP), all of which could exacerbate the downward trend in EPS. Additionally, management anticipates that efforts to recover the Star ratings will necessitate increased investments, potentially leading to a 10% shortfall in FY27 EPS estimates.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares